2017/4 GaBI Journal Table of Contents

Contents

Editor’s Letter

Fourth and final issue of GaBI Journal’s sixth volume

Letters to the Editor

Clear naming, traceability of biological medicines will protect patients

Comment on the non-biological complex drugs paper

Commentary

Global policies on pharmacy-mediated substitution of biosimilars: a summary

Original Research

Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies

Review Article

Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Perspective

40th anniversary of essential medicines: a loud call for improving its access

Guidelines

Biosimilars in Germany: guidance of the Drug Commission of the German Medical Association

Special Report

Building stakeholder confidence in biosimilar medicines through evidence-based information sharing

USA and Europe differ in interchangeability of biosimilars

Meeting Report

Perspectives on the future of pegfilgrastim biosimilars

Abstracted Scientific Content

Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar

A comparison of European and US generic drug markets

Research News

HIV patients will accept generic treatments

Source URL: https://gabi-journal.net/20174-gabi-journal-table-of-contents.html